The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 14, 2025

Filed:

May. 02, 2024
Applicant:

Helsinn Healthcare SA, Pazzallo-Lugano, CH;

Inventors:

Claudio Giuliano, Como, IT;

Claudio Pietra, San Martino Siccomario, IT;

Silvina Garcia Rubio, Princeton, NJ (US);

Angelo Guainazzi, New York, NY (US);

Marielle Martinez-Loi, Biasca, CH;

Assignee:

Helsinn Healthcare SA, Pazzallo-Lugano, CH;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/4468 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4468 (2013.01);
Abstract

The new compound 3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)-1-methyl-1-(1,3,3-trimethylpiperidin-4-yl)urea monohydrochloride salt has a high capability to permeate through the blood-brain barrier and to display, at central nervous system level, a consistent ghrelin agonist activity; the compound is effective in the treatment and/or prevention of a medical condition mediated by the ghrelin receptor in the central nervous system. In particular, in experimental tests, the compound has shown high efficacy in the treatment of neurotoxic damage, with a useful combined pattern of neuroprotective effects both at central and peripheral level. The compound is further useful in the treatment of conditions which require a reduction of the heart rate. The compound is pharmacologically active at low to moderate doses, thus showing a favourable therapeutic index.


Find Patent Forward Citations

Loading…